Vertex Pharmaceuticals has earned milestone and option fees totalling $5 million from Glaxo Wellcome and Kissei Pharmaceutical. The payments are related to the development and commercialization of VX-478, an HIV protease inhibitor designed by Vertex. The three companies are engaged in an international development program for the product.
GW has paid $2 million, based on the mid-December start of Phase II/III clinical trials of VX-478. With its $3 million payment, Kissei has exercised its option to develop and commercialize VX-478 in 15 additional Asian territories including Hong Kong, the Philippines, Singapore, Taiwan, Thailand and Vietnam. It already has rights in Japan and China. GW has rights in the rest of the world.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze